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Background: Structural imaging studies of cannabis users have found evidence of
both cortical and subcortical volume reductions, especially in cannabinoid receptor-rich
regions such as the hippocampus and amygdala. However, the findings have not been
consistent. In the present study, we examined a sample of adult heavy cannabis users
without other substance abuse to determine whether long-term use is associated with
brain structural changes, especially in the subcortical regions.
Method: We compared the gray matter volume of 14 long-term, heavy cannabis users
with non-using controls. To provide robust findings, we conducted two separate studies
using two different MRI techniques. Each study used the same sample of cannabis users
and a different control group, respectively. Both control groups were independent of
each other. First, whole-brain voxel-based morphometry (VBM) was used to compare the
cannabis users against 28 matched controls (HC1 group). Second, a volumetric analysis
of subcortical regions was performed to assess differences between the cannabis users
and a sample of 100 matched controls (HC2 group) obtained from a local database of
healthy volunteers.
Results: The VBM study revealed that, compared to the control group HC1, the
cannabis users did not show cortical differences nor smaller volume in any subcortical
structure but showed a cluster (p < 0.001) of larger GM volume in the basal ganglia,
involving the caudate, putamen, pallidum, and nucleus accumbens, bilaterally. The
subcortical volumetric analysis revealed that, compared to the control group HC2,
the cannabis users showed significantly larger volumes in the putamen (p = 0.001)
and pallidum (p = 0.0015). Subtle trends, only significant at the uncorrected level,
were also found in the caudate (p = 0.05) and nucleus accumbens (p = 0.047).
Moreno-Alcázar et al. Brain Abnormalities by Cannabis Use
Conclusions: This study does not support previous findings of hippocampal and/or
amygdala structural changes in long-term, heavy cannabis users. It does, however,
provide evidence of basal ganglia volume increases.
Keywords: basal ganglia, cannabis, long-term users, MRI, voxel-based morphometry
INTRODUCTION
Cannabis is the most commonly used illicit drug worldwide,
consumed mainly by adolescents and young adults (1). Although
a large number of people, especially cannabis users, consider
cannabis to be a harmless drug, there is still debate about
the possible behavioral and neurobiological consequences of
cannabis use (2, 3).
Animal studies have consistently shown that 19-
tetrahydrocannabinol (THC), the main psychoactive component
of cannabis (4), induces neurotoxic changes in brain regions
rich in CB1 cannabinoid receptors such as the hippocampus (5),
amygdala (6), and cerebral cortex (4), affecting the processes
associated with the maturational refinement of cortical neuronal
networks (7, 8). A recent systematic review has shown that
acute and chronic effects of cannabis impair human cognition,
especially in the domains of verbal learning, attention, and
memory (9), while the effects on other cognitive functions such
as executive functions (10, 11) and IQ (12) remain unclear.
However, use of this drug has been associated with social
problems and a range of psychiatric disorders such anhedonia,
anxiety, depression, and an increased risk of psychotic symptoms,
especially in adolescent users (13–15).
In contrast to the animal literature, much less is known about
the neurobiological consequences of cannabis use in the human
brain. As a result of the growing concern about the use of
this drug, several human studies using neuroimaging techniques
were carried out, with inconsistent or inconclusive results. For
example, some studies have not found regional or global gray
matter (GM) abnormalities associated with cannabis use (16, 17)
while others have shown volume reduction, especially in the
amygdala, the hippocampus and parts of the prefrontal and the
medial temporal cortex (3, 8, 18–24), or larger GM volume
in the cerebellum (25). A study carried out by Lorenzetti et
al. (19) analyzed other brain regions, using the same sample
as Yücel et al. (18) such as the orbitofrontal cortex, the
anterior cingulate cortex or the pituitary gland, and did not
detect significant differences between cannabis users and healthy
controls. On the contrary, Price et al. (26) identified lower GM
volume in the orbitofrontal cortex, which was associated with
attentional deficits. Similarly, Gilman et al. (27) assessed the
nucleus accumbens and the amygdala using different types of
neuroimaging analysis. The authors found a greater GM density
in both left regions, and also showed a greater GM volume in
the left nucleus accumbens. In contrast, these results were not
replicated in another subsequent study (28), in which the authors
used the same analysis techniques as those used by Gilman et al.
(27) to evaluate the nucleus accumbens, amygdala, hippocampus,
and cerebellum. Nevertheless, it should be mentioned that
inclusion criteria regarding cannabis use in the healthy subjects
of the study by Weiland et al. (28) required only the report of no
cannabis use in the past 3 months. Therefore, these results cannot
be extrapolated to long-term cannabis users.
In summary, taking into account the results of the last
systematic review carried out by Nader et al. (29), the most
important and replicated alterations in cannabis users have been
identified in CB1 rich areas such as the hippocampus (3, 18,
23). Morphological changes in other brain regions are more
controversial. Differences in the inclusion criteria allowed in
the samples, and in particular those related to consumption,
could be contributing to the mixed results. Another possible
source of uncertainty is the use of different neuroimaging
techniques, which may have different sensitivities to detect subtle
morphological changes. Future studies using stricter and more
appropriate criteria for collecting the sample, and employing
different neuroimaging techniques to replicate results, will allow
researchers to drawn more solid conclusions in this respect.
Based on previous structural findings, the present study
aimed to further investigate the question of brain structural
changes associated with cannabis consumption. We compared
the GM volume of long-term, heavy cannabis users and
matched controls. To provide more robust findings, two separate
studies using two different MRI techniques were conducted.
Each study used the same sample of cannabis users and a
different control group, respectively. Both control groups were
independent of each other. In the first study, whole-brain
voxel-based morphometry (VBM) was used to compare the
cannabis users against healthy controls. In the second study,
a volumetric analysis of subcortical regions was performed to
assess for differences between the cannabis users and a different
sample of matched controls obtained from a local database of
healthy subjects. We hypothesize that cannabis users will show
neuroanatomical differences, especially in those brain regions
rich in cannabinoids receptors and in regions implicated in
substance abuse.
METHODS
Participants
Fourteen long-term heavy cannabis adult users were recruited via
three sources in Barcelona: (i) attenders at a specialist clinic in
Vall de Hebron Hospital who wished to stop using the drug; (ii)
inpatients in a unit in BenitoMenni hospital specializing in drug-
related disorders; (iii) a cannabis users association. They were
questioned about lifetime drug use using the relevant section
of the Structured Clinical Interview for DSM-IV-TR Axis I
Disorders (SCID-I) (30) and also screened for psychopathology
using the Computerized Diagnostic Interview Schedule IV (C
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DIS-IV) (31). The cannabis users were matched 1:2 with 28
non-drug-using controls (HC1 group) who were recruited via
poster and web-based advertisement in the hospital and local
community, plus word-of-mouth requests from staff in the
research unit. They also were clinically interviewed to assess
history of major mental illness.
Inclusion criteria were being 18–65 years of age, right handed
and having an IQ score of >70. Cannabis users must have used
cannabis at a minimum rate of 3 joints per day for at least 5 years
and be willing to abstain from cannabis use for at least 24 h prior
to assessment. Healthy controls were required to have not used
cannabis at all during the last year, and underwent a screening
interview to confirm that they did not have a lifetime history of
more than sporadic use of this or other drugs. This last criterion
was defined as a maximum consumption of a drug of 10 or more
times in 1 year. Exclusion criteria were any history of neurological
disorders or serious head injury; any history of mental illness
and/or treatment with psychotropic medication; daily use of
other drugs (cocaine, heroin, amphetamine, benzodiazepines,
etc) or a lifetime history of alcohol abuse/dependency (defined
according to DSM IV criteria), and MRI contraindications. In
all cases, social alcohol use was permitted: following Spanish
guidelines (32), the upper limit for this was set at ≤17 standard
drink unit [(SDU); every SDU contains 10 g of pure alcohol] per
week or 6 SDU in 24 h no more than once per month (men) and
≤11 SDU per week or 5 SDU in 24 h no more than once per
month (women).
As well as being recruited to be similar in age and sex, the
two groups were matched for estimated IQ using the Word
Accentuation Test (Test de Acentuación de Palabras, TAP)
(33, 34). This test is conceptually similar to the UK National
Adult Reading Test (NART) (35) and the US Wide Range of
Achievement Test (36) and requires pronunciation of Spanish
words whose accents have been removed.
For the volumetric analysis of subcortical regions, the
cannabis users were compared to a separate sample of 100 healthy
matched adults collected from a local database of healthy subjects
(HC2 group). They met the same inclusion and exclusion criteria
as the HC1 in the VBM study.
All participants gave written informed consent. The research
protocol (number PR-2012-03) was approved by the Clinical
Research Ethics Committee of the Sisters Hospitallers (Comité
de Ética de Investigación Clínica de las Hermanas Hospitalarias).
All procedures were carried out according to the Declaration of
Helsinki.
MRI Data Acquisition
All participants underwent structural MRI scanning in the same
1.5 Tesla GE Signa scanner (General Electric Medical Systems,
Milwaukee, Wisconsin, USA) located at the Sant Joan de Déu
Hospital in Barcelona (Spain). High resolution structural T1MRI
data were acquired with the following acquisition parameters:
matrix size 512 × 512; 180 contiguous axial slices; voxel
resolution 0.47 × 0.47 × 1 mm3; echo (TE), repetition (TR),
and inversion (TI) times 3.93, 2,000, and 710 ms respectively; flip
angle 15◦.
Voxel-Based Morphometry
Structural data were analyzed with FSL-VBM, which implements
an optimized voxel-based morphometry protocol (37) carried
out with FSL tools (FMRIB Software Library, Analysis Group,
FMRIB, Oxford, UK). FSL-VBM yields a measure of difference
in local GM volume between populations. In a first step,
structural images were brain-extracted using BET. Next, tissue-
type segmentation was carried out and the resulting GM partial
volume images were then aligned to Montreal Neurological
Institute (MNI 152) standard space using the FSL tools FLIRT
and FNIRT. The resulting images were averaged to create a study-
specific template, to which the native GM images were then non-
linearly re-registered. The registered partial volume images were
then modulated to correct for local expansion or contraction.
The modulated segmented images were then smoothed with an
isotropic Gaussian kernel with a sigma of 4mm.
Comparison of the cannabis users and the control group HC1
was carried out using a voxel-wise general linear model (GLM)
and permutation-based non-parametric testing, correcting for
multiple comparisons. These were made with the “randomize”
tool implemented in FSL, using a cluster-based thresholding
method with 10,000 iterations and initial cluster-forming
threshold Z ≥ 3.0. Clusters were assessed for significance at p <
0.05, fully corrected for multiple comparisons across space.
As both groups were well matched for all demographic
variables (for more details see the Results section) including age,
sex, estimated IQ, as well as tobacco and alcohol consumption,
the main analysis was performed without including covariates in
the GLM. In order to investigate the effects of other consumption
variables on the results, and to identify any potential correlation
among these variables and GM volume, we conducted a
separate complementary analysis including tobacco and alcohol
consumption in the GLM. For completeness, we carried out an
additional analysis by using the remaining variables, age, sex, and
estimated IQ as covariates.
Anatomical locations of the significant clusters were
determined with reference to the Harvard–Oxford cortical and
subcortical structural atlases integrated into FSLView (part of
FSL) and the AAL atlas (Anatomical Automatic Labeling), a
macro-anatomical parcellation of the single subject MNI-space
template brain within MRIcron software (http://people.cas.sc.
edu/rorden/mricron/index.html).
Subcortical Volumetric Analysis
The volume of subcortical structures was examined using
FIRST, a model-based segmentation and registration tool part
of FSL (38). This technique computes the volume of a
number of predefined subcortical regions, including the caudate
nucleus, putamen, pallidum, nucleus accumbens, hippocampus,
amygdala, thalamus, and brainstem. The performance of FIRST
has been shown to be comparable or better than other automated
methods (38). The measurement of the nucleus accumbens and
amygdala with 1.5T data has been considered to be difficult. As
a further check, therefore, we verified that our means values in
controls are very similar (i.e., plus/minus one standard deviation
from the mean) to those reported in two independent studies
using manual segmentation (39) and FIRST with 3.0T data (40).
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The subcortical volumes were corrected for subject
head size (i.e., intra-cranial volume) to obtain normalized
volumes. This was achieved by multiplying the volume
of each subcortical structure by the volumetric scaling
factor resulting from the SIENAX tool (part of FSL). The
normalized subcortical volumes of the cannabis users were
compared with the volumes of matched adults collected
from a local database of healthy subjects (HC2 group). In
both groups, the structural MRI datasets were acquired
on the same scanner and using the same MRI sequence.
Moreover, the volumes were computed using the same FIRST
tool.
Comparison of the cannabis users and the HC2 group was
carried out using a GLM. The significance level was set at p
< 0.05, corrected for multiple comparisons using Bonferroni
correction. As in the main analysis of the previous VBM
study, both groups were well matched for all demographic
variables, including age, sex, and estimated IQ, hence, these
were not included in the GLM. In this case, it was not possible
to study the effect of tobacco and alcohol consumption due
to lack of data in controls. Reported volumes were averaged
across hemispheres. This approach was motivated by our VBM
results, which produced bilateral and symmetrical significant
differences (see Results section) and to reduce the total number
of comparisons. Importantly, we explicitly checked that this
approach did not mask any laterality effect by performing
two different t-tests. Specifically, we verified in both cannabis
users and controls that the mean volume of each structure
is not different between hemispheres (i.e., all the p-values
resulting from all tests were higher than p > 0.38). Moreover,
for each individual structure, we verified that the inter-group
differences between hemispheres are not different (i.e., all
the p-values resulting from all tests were higher than p >
0.42).
Finally, a further analysis was conducted in cannabis users
to examine if the volume measures correlate with the drug
use measures: duration of cannabis use, age of onset and
cannabis consumption per day. Pearson’s linear correlation
coefficients were calculated together with their p-values using
a Student’s distribution. The significance level was set at
p < 0.05, corrected for multiple comparisons using Bonferroni
correction.
TABLE 1 | Sociodemographic and substance use characteristics of the samples.
CAN (N = 14)
Mean (SD)
HC1 (N = 28)
Mean (SD)
HC2 (N = 100)
Mean (SD)
CAN vs. HC1
p-value
CAN vs. HC2
p-value
CAN vs. HC1
X2 Value
CAN vs. HC2
X2 Value
Age (years) 30.14 (5.21) 31.29 (6.58) 31.31 (6.93) 0.57 0.56
Gender (male/female) 4/10 8/20 40/60 1.00 0.41
Race (Caucasian/others) 14/0 28/0 100/0 . .
Estimated IQ (TAP) 101.08 (7.14) 104.04 (5.46) 103.43 (8.18) 0.15 0.32
Duration of cannabis use (years) 14.36 (6.69) – –
Age of onset 17.07 (2.92) – –
Cannabis consumption (joints/day) 8.36 (3.81) – –
Tobacco consumption (cigarettes/day) 5.58 (6.52) 1.74 (3.80) 0.08
Tobacco consumption (n◦ subjects) 8 5 <0.01
Alcohol consumption/week (drink) 1.08 (1.31) 0.83 (0.83) 0.58
Alcohol consumption (n◦ subjects) 6 8 0.35
CAN, Cannabis users; HC1, Healthy controls 1 analysis; HC2, Healthy controls 2 analysis, SD, standard deviation; n◦, number.
FIGURE 1 | VBM comparison between the cannabis users and the control group HC1. Regions showing significant larger volume in the cannabis users are shown in
red-yellow. The color-bar shows the z-score scale. The right side of the images represents the right side of the brain.
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FIGURE 2 | Three-dimensional view showing the spatial localization of volume
abnormalities in different regions of the basal ganglia: (A) caudate nucleus, (B)
putamen, (C) pallidum, and (D) nucleus accumbens. Basal ganglia structures
are depicted in red while regions showing volume alterations are shown in blue.
RESULTS
Demographic Characteristics of the Two
Groups
Sociodemographic and substance use characteristics of
participants are shown in Table 1. It can be seen that the
three groups used in both analyses were well matched for age,
sex, race, and estimated IQ. Cannabis users and the control
group HC1 did not show significant differences in tobacco and
alcohol consumption, although there were differences in the
number of smokers per group. However, the comparison with
the control group HC2 could not be carried out due to lack of
data. The cannabis users had used the drug heavily for fourteen
years on average, with an average age of onset of seventeen.
VBM Comparison of Cannabis Users and
Controls
The main analysis without using covariates revealed that,
compared to the control group HC1, the cannabis users did not
show cortical differences nor smaller volume in any subcortical
structures but showed a cluster of larger GM volume in the
basal ganglia [p < 0.001, three main peaks in MNI standard
space: peak1 (−18, 8, −2), z-score = 5.53; peak2 (24, −8, 8), z-
score = 4.33; peak3 (12, 18, 10), z-score = 4.05; see Figure 1].
This cluster included parts of the caudate, putamen, pallidum
and nucleus accumbens, bilaterally. In order to better visualize
the spatial location and overlapping within these structures, a
three-dimensional view of these subcortical regions is depicted
in Figure 2.
The complementary analysis using tobacco and alcohol
consumption as covariates in the GLM revealed a very similar
pattern of inter-group differences, affecting the same subcortical
structures in both hemispheres. In particular, the cannabis users
showed two bilateral clusters of larger GM volume [cluster1 on
left hemisphere, p = 0.016, main peak in MNI standard space
(−18, 8, −2), z-score = 5.28; cluster2 on right hemisphere, p
= 0.013, main peak in MNI standard space (22, 2, −2), z-score
= 5.03). The analysis did not find any cluster with significant
positive or negative correlation between GM volume and tobacco
or alcohol consumption. Similarly, the complementary analysis
using age, sex, and IQ as covariates revealed two bilateral clusters
of larger GM volume [cluster1 on left hemisphere, p = 0.02,
main peak in MNI standard space (−18, 8, −2), z-score = 5.09;
cluster2 on right hemisphere, p = 0.016, main peak in MNI
standard space (20, 16, −10), z-score = 5.03]. The analysis did
not reveal any significant positive or negative correlation between
the covariates and GM volume.
Comparison of Subcortical Volumes in the
Cannabis Users Against a Database of
Healthy Subjects
After correcting for multiple comparisons, the analysis did not
reveal any subcortical structure with larger volume in the HC2
group. In contrast, the cannabis users depicted significant larger
volumes in the putamen (p = 0.001) and pallidum (p = 0.0015).
Interesting, subtle trends, only significant at the uncorrected
level, were also found in the caudate (p = 0.05) and nucleus
accumbens (p= 0.047). The findings are shown in Figure 3.
The correlation analysis in the cannabis users did not show
any significant positive or negative correlation between the
subcortical volumes and the duration of cannabis use, the age of
onset, and the cannabis consumption per day.
For completeness of this report, in Table 2 we provide
information about the mean values and standard deviation of all
the evaluated structures in both populations.
DISCUSSION
The aim of this study was to evaluate whether there are structural
brain differences between heavy cannabis users and healthy
subjects, particularly in brain regions rich in cannabinoids
receptors and in regions implicated in substance abuse A
modulated VBM analysis showed that cannabis users did not
present cortical regional differences nor smaller volume of GM
in any subcortical structures in comparison with the healthy
controls (HC1) group. However, the analysis showed a significant
cluster of larger GM volume in the basal ganglia, involving the
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FIGURE 3 | Box plots showing the comparisons of subcortical volume in the caudate, putamen, pallidum, accumbens, hippocampus, amygdala, thalamus, and
brainstem between cannabis users and the control group HC2. **Individual tests significant at a corrected p < 0.05, *Significant only at the uncorrected level p < 0.05.
caudate, putamen, pallidum and nucleus accumbens, bilaterally.
The first complementary analysis did not reveal any significant
positive or negative correlation between tobacco and alcohol
consumption and the GM volume. However, the lack of results
in this analysis were to be expected due to the subjects’ low
levels of consumption. The second complementary correlation
analysis also showed no difference between age, sex, IQ, and the
GM volume. Therefore, these variables also had no influence
on the main results found in this study. The VBM findings
were also supported by a comparison of the volumes of a
range of anatomically defined subcortical structures between
the cannabis users against a large database of healthy subjects
(HC2 group), which also showed larger volumes for the putamen
and pallidum nuclei. The caudate and accumbens were not
statistically significant after correcting for multiple comparisons,
but we observed a trend at the uncorrected level (p< 0.05). These
volumetric changes did not correlate with any drug use measure.
Our finding of larger basal ganglia volume is similar to
that of Gilman et al. (27), who compared 20 recreational
adolescent users and 20 non-users using VBM and found a
subcortical cluster of increased volume involving the left nucleus
accumbens/putamen and amygdala. The increase in the left
accumbens, but not that in the amygdala, was also found in
a subsequent ROI analysis and was correlated with frequency
of drug use. These results are consistent with animal studies
which showed an increase in the number of dendritic branches
and an increase in density of dendritic spines in the nucleus
accumbens in amphetamine, cocaine, nicotine and cannabis
treated rats (27). In addition, a recent meta-analysis of functional
neuroimaging studies carried out by Yanes et al. (41) observed
TABLE 2 | Volume of subcortical structures.
Structures (mm3) HC2 (N = 100) CAN (N = 14)
Mean (SD) Mean (SD)
Caudate 4,686.3 (454.2) 4,906.4 (393)
Putamen 6,549.5 (454.4) 6,996.5 (539.8)
Pallidum 2,190.4 (136.9) 2317 (131)
Accumbens 593.7 (99.9) 642.5 (83.7)
Amygdala 1,462.1 (205.9) 1,447.4 (210.6)
Hippocampus 4997.9 (478.7) 5,025.3 (571.1)
Thalamus 10,278.1 (645.2) 10,424.3 (491.6)
Brainstem 30,169.1 (2102) 31,024 (1985.1)
Reported volumeswere averaged across hemispheres and corrected for subject head size
(i.e., intra-cranial volume). This was done by multiplying the volume of each subcortical
structure by the volumetric scaling factor resulting from the SIENAX tool (part of FSL). This
operation transforms the volumes from the native space to the average MNI space. CAN,
Cannabis users; HC2, Healthy controls 2; SD, standard deviation.
an increase in activation within the striatum among cannabis
users compared to the controls in cognitive, social cognitive,
affective, perceptual, and/or motor tasks. Interestingly, increased
basal ganglia volume, as we found in cannabis users, has also
been reported in association with long-term use of another
drug, cocaine. Ersche et al. (42) compared 60 chronic cocaine-
dependent individuals with 60 healthy controls using VBM,
and found evidence of widespread cortical GM reductions, but
also a significant increase in subcortical GM volume, which
affected basal ganglia structures including the putamen, caudate
nucleus and pallidum, and also the cerebellum. Cocaine, like
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other stimulants such as methamphetamine, exerts an important
both acute and chronic neurotoxic changes in dopaminergic
neurons, and potentially its use could be responsible for the
basal ganglia changes by inducing neuroinflammatory processes.
In this way, for example, two volumetric studies documented
that active methamphetamine users showed an increase in the
basal ganglia, including the caudate nucleus, globus pallidus,
and putamen (43, 44), while another study showed that those
users who were abstinent for more than 20 months presented
normal volumes in these cerebral regions, but a minor alteration
in the shape of the corpus callosum (45). These results suggest
that the use of methamphetamine could induce inflammation
or reactive gliosis, which may normalize with longer abstinence
(46). Taking into account our results, the same neurobiological
process may be occurring in chronic cannabis users. In fact, one
study carried out in adolescent rats showed that THC exposition
induces a persistent neuroinflammatory state in the prefrontal
cortex, characterized by increased levels of the inflammatory
mediators, TNF-α, iNOS, and COX-2, and reduction of the anti-
inflammatory cytokine, IL-10 (47). However, further research,
in both animal and humans, is needed to confirm this
hypothesis and to better understand the neurobiological effects of
cannabis.
On the contrary, our data do not support the results of
previous studies which found smaller right ventral striatum
volumes (∼3.5%) in cannabis users (48), or found no significant
differences between users and healthy controls (21, 28). On
the other hand, our findings are notably different from those
who reported reduced hippocampal (3, 18, 20, 22, 23, 49) and
amygdala volume (18, 48), as well as a smaller volume in cortical
areas (24, 26). However, as noted in the introduction, other
studies have had negative findings for these structures (21, 23),
including one in which the participants had heavy use for at
least 2 years (25) and another in which they had taken the drug
more than 5,000 times (17). A recent large study by Pagliaccio et
al. (48) suggests a possible reason for these discrepant findings:
they examined the influence of both hereditary factors and
cannabis use on the volumes of the whole brain, hippocampus,
amygdala, ventral striatum, and orbitofrontal cortex in a sample
of 483 individuals made up of 3–4 siblings, and in some cases
twin pairs. The left amygdala and right ventral striatum were
found to be smaller (by 2.3 and 3.5%, respectively in those with
a history of cannabis users), but the association between left
amygdala volume and cannabis use emerged as being largely
a function of shared genetic factors (whether this also applied
to the smaller right ventral striatum volume found in cannabis
users was unclear). These results are of great interest because
they could suggest that brain alterations found in cannabis users
could be explained by genetic factors and not exclusively by
drug use. However, further research is needed to confirm this
hypothesis.
The main limitation of this study is the relatively small
sample size. However, with the subcortical volumetric analysis,
we replicated the findings from the VBM analysis. The fact that
drug users frequently take multiple drugs, and often alcohol as
well, probably means that for the foreseeable future findings
about the consequences on the brain of long-term heavy cannabis
use will have to rely on mega-analysis or meta-analysis using data
from a number of relatively small studies. Although all healthy
controls were clinically interviewed and have never had a history
of more than sporadic use of cannabis or other drugs, data on
substance abuse in the past were not systematically collected for
the majority of the 100 healthy controls of the second analysis
(HC2 group) (especially tobacco and standard alcohol units
consumption). This lack of information has not allowed us to
study any potential effect related to other consumption variables.
However, in the first study (HC1 group), we did not find any
correlation between these variables and GM volume.
To conclude, despite the small sample of our VBM study,
the results partially support our hypothesis, which suggested
that long-term cannabis use may be associated with changes
in critical brain regions implicated in substance abuse such as
the basal ganglia. Further research with larger samples and with
multimodal analysis techniques are needed to confirm these
results.
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